Aicardi-Goutières Syndrome (AGS) is a monogenic leukodystrophy with pediatric onset, clinically characterized by a variable degree of neurologic impairment. It belongs to a group of condition called type I interferonopathies that are characterized by abnormal overproduction of interferon alpha, an inflammatory cytokine which action is mediated by the activation of two of the four human Janus Kinases. Thanks to an ever-increasing knowledge of the molecular basis and pathogenetic mechanisms of the disease, Janus Kinase inhibitors (JAKIs) have been proposed as a treatment option for selected interferonopathies. Here we reported the 24 months follow-up of the fifth AGS patient treated with ruxolitinib described so far in literature. The treatment was globally well tolerated; clinical examinations and radiological images demonstrated a progressively improving course. It is however to note that patients presenting with mild and spontaneously improving course have been reported. Large natural history studies on AGS spectrum are strongly required in order to get a better understanding of the results emerging from ongoing therapeutic trials on such rare disease.

Ruxolitinib in Aicardi-Goutières syndrome / E. Mura, S. Masnada, C. Antonello, C. Parazzini, G. Izzo, J. Garau, D. Sproviero, C. Cereda, S. Orcesi, P. Veggiotti, G. Zuccotti, D. Dilillo, F. Penagini, D. Tonduti. - In: METABOLIC BRAIN DISEASE. - ISSN 0885-7490. - (2021). [Epub ahead of print] [10.1007/s11011-021-00716-5]

Ruxolitinib in Aicardi-Goutières syndrome

E. Mura
Primo
;
P. Veggiotti;G. Zuccotti;F. Penagini;D. Tonduti
2021

Abstract

Aicardi-Goutières Syndrome (AGS) is a monogenic leukodystrophy with pediatric onset, clinically characterized by a variable degree of neurologic impairment. It belongs to a group of condition called type I interferonopathies that are characterized by abnormal overproduction of interferon alpha, an inflammatory cytokine which action is mediated by the activation of two of the four human Janus Kinases. Thanks to an ever-increasing knowledge of the molecular basis and pathogenetic mechanisms of the disease, Janus Kinase inhibitors (JAKIs) have been proposed as a treatment option for selected interferonopathies. Here we reported the 24 months follow-up of the fifth AGS patient treated with ruxolitinib described so far in literature. The treatment was globally well tolerated; clinical examinations and radiological images demonstrated a progressively improving course. It is however to note that patients presenting with mild and spontaneously improving course have been reported. Large natural history studies on AGS spectrum are strongly required in order to get a better understanding of the results emerging from ongoing therapeutic trials on such rare disease.
Aicardi-Goutières syndrome; Interferonopathy; Janus Kinase inhibitor; Leukodystrophy; Ruxolitinib; Treatment
Settore MED/39 - Neuropsichiatria Infantile
15-mar-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
RuxolitinibInAicardi-Goutières.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 673.03 kB
Formato Adobe PDF
673.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824339
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact